Is INSMED Inc (INSM) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.9% / 30% | 4.7% / 30% | 0.5% / 30% | 0.0% / 5% | ✓ HALAL |
| DJIM | 1.9% / 33% | 4.7% / 33% | 0.5% / 33% | 0.0% / 5% | ✓ HALAL |
| MSCI | 25.9% / 33% | 63.1% / 33% | 6.2% / 33% | 0.0% / 5% | ✗ NOT HALAL |
| S&P | 1.9% / 33% | 4.7% / 33% | 0.5% / 33% | 0.0% / 5% | ✓ HALAL |
| FTSE | 25.9% / 33% | 63.1% / 33% | 6.2% / 50% | 0.0% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 79.7% | |
| Operating Margin | -94.6% | |
| Net Margin | -210.5% | |
| Return on Equity (ROE) | -249.3% | |
| Return on Assets (ROA) | -29.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$935M |
| Free Cash Flow | -$968M |
| Total Debt | $587M |
| Debt-to-Equity | 101.4 |
| Current Ratio | 3.8 |
| Total Assets | $2.3B |
Price & Trading
| Last Close | $147.60 |
| 50-Day MA | $150.34 |
| 200-Day MA | $149.48 |
| Avg Volume | 2.4M |
| Beta | 1.2 |
|
52-Week Range
$60.40
| |
About INSMED Inc (INSM)
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is INSMED Inc (INSM) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), INSMED Inc is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is INSMED Inc's debt ratio?
INSMED Inc's debt ratio is 1.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 25.9%.
What are INSMED Inc's key financial metrics?
INSMED Inc has a market capitalization of $31.3B, and revenue of $606M. The company maintains a gross margin of 79.7% and a net margin of -210.5%. Return on equity stands at -249.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.